The Washington Post

GlaxoSmithKline buys Human Genome Sciences for $3.6B


Human Genome Sciences' headquarters in Rockville. (Jeffrey MacMillan/Capital Business)

Glaxo has extended multiple buyout offers since April to both the HGS board of directors and its shareholders that valued the company at $2.6 billion, or $13 per share, but the company repeatedly rejected them as too low.

This latest agreement will fetch $14.25 per share in cash for HGS, a transaction value worth about $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, the companies said.

The deal brings an end to what had become an increasingly heated battle for control of the company.

Glaxo had attempted to bypass the board and purchase stock directly from investors. HGS then thwarted that effort with a poison pill, but gained a lawsuit from some disgruntled shareholders in response.

The two firms are development and marketing partners on several drugs, including Benlysta, which was approved by the Food and Drug Administration last year to treat systemic lupus.

Comments
Show Comments
0 Comments
Washington Post Subscriptions

Get 2 months of digital access to The Washington Post for just 99¢.

A limited time offer for Apple Pay users.

Buy with
Cancel anytime

$9.99/month after the two month trial period. Sales tax may apply.
By subscribing you agree to our Terms of Service, Digital Products Terms of Sale & Privacy Policy.

Get 2 months of digital access to The Washington Post for just 99¢.

Most Read
Read stories based on reporting for “Trump Revealed,” a broad, comprehensive biography of the life of the president-elect.

business

capitalbusiness

Success! Check your inbox for details.

See all newsletters

Close video player
Now Playing